Ketamine liquid preparation and use thereof

By developing ketamine liquid preparations for oral mucosal administration, the tolerance and absorption of existing ketamine nasal sprays have been solved, bioavailability has been improved, the risk of abuse has been reduced, and the needs of more patients with depression have been met.

WO2024240033A1PCT designated stage expired Publication Date: 2024-11-28YICHANG HUMANWELL PHARMA CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/093448
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-19
Filing Date
2024-05-15
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Existing ketamine nasal sprays have poor tolerance to nasal mucosa, fast absorption but low bioavailability, and high concentrations increase the risk of abuse, which cannot meet the needs of all patients with depression.

Method used

Develop a ketamine liquid preparation, administered through oral mucosa, containing 0.5% w/v to 8.5% w/v ketamine or its salt, combined with lower alcohols and water, with a pH range of 2.5 to 7.5, increasing bioavailability and reducing abuse risk.

Benefits of technology

It improves the bioavailability of ketamine, simplifies the administration process, reduces the irritation to the mucosa, reduces side effects, expands the application range of antidepressants, and reduces the treatment cost.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024093448_28112024_PF_FP_ABST
    Figure CN2024093448_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present application discloses a ketamine liquid preparation. The ketamine liquid preparation comprises ketamine or a pharmaceutically acceptable salt thereof, at least two lower alcohols and water, and the pH value of the liquid preparation is 2.5-7.5. The liquid preparation of the present application is administered via oral mucosa, and has simple formula, high stability, fast absorption, high bioavailability, simple administration mode and good compliance. The preparation of the present application can be used for the prevention, alleviation or treatment of major depression, unipolar depression, treatment-resistant depression, intractable depression, agitated depression, and bipolar depression.
Need to check novelty before this filing date? Find Prior Art

Description

Ketamine liquid preparation and use thereof

[0001] This application claims priority to Chinese patent application No. 202310573687.7, filed on May 19, 2023, entitled “Ketamine Liquid Preparation and Uses Thereof,” the contents of which should be understood as being incorporated into this application by reference. Technical Field

[0002] The present application relates to, but is not limited to, the field of pharmaceutical preparation technology, and in particular to a ketamine liquid preparation and its use as an antidepressant drug. Background Art

[0003] Depression is a form of manic-depressive illness characterized by low mood, slowed thinking, and reduced speech and movement. Depression severely impacts patients' lives and work, placing a heavy burden on families and society. Approximately 15% of patients with depression die by suicide. A joint study by the World Health Organization, the World Bank, and Harvard University indicates that depression has become the second-leading cause of disease burden in China.

[0004] In recent years, ketamine has garnered considerable attention as a psychiatric medication for depression, with numerous reports demonstrating its antidepressant effects. Ketamine, a rapidly acting antidepressant, may achieve its antidepressant effects by increasing monoamine release or inhibiting presynaptic monoamine reuptake, thereby elevating brain monoamine levels.

[0005] Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist. Currently, most ketamine used in clinical practice is a racemic form, containing two enantiomers, namely dextrorotatory ketamine and levorotatory ketamine.

[0006] An antidepressant drug with a new mechanism developed by Johnson & Johnson in the United States is a nasal spray with esketamine hydrochloride as the main drug. This product has a fast-acting, long-lasting and powerful therapeutic effect on patients with refractory depression and suicidal tendencies, and was approved for its first launch in the United States in March 2019.

[0007] Although esketamine has achieved excellent antidepressant effects through nasal administration, it cannot meet the medical needs of patients with nasal inflammation or poor nasal mucosal tolerance. In addition, the volume of esketamine hydrochloride nasal spray preparations currently on the market is relatively small. To achieve a therapeutic dose, the concentration of esketamine hydrochloride in the preparation is relatively high, close to the water solubility saturation of esketamine. This high concentration of esketamine hydrochloride solution may increase the risk of ketamine abuse to a certain extent. Furthermore, pharmacokinetic studies have found that esketamine is rapidly absorbed when administered through nasal spray, but poorly absorbed and has low bioavailability. Therefore, in order to further expand the clinical application of ketamine in the treatment of depression, meet the needs of more patients with depression, reduce treatment costs, and alleviate the burden on patients' families, it is urgent to consider other effective routes of administration.

[0008] Summary of the Invention

[0009] The present application provides a ketamine liquid preparation, which is administered through the oral mucosa. The preparation of the present application has a simple formula, high stability, rapid absorption, simple administration method and good compliance.

[0010] In a first aspect, the present application provides a ketamine liquid preparation for oral mucosal administration, comprising ketamine or a pharmaceutically acceptable salt thereof at a concentration of 0.5% w / v to 8.5% w / v, at least two lower alcohols, and water.

[0011] A second aspect of the present application specifically provides a ketamine liquid preparation, which includes ketamine or a pharmaceutically acceptable salt thereof, at least two lower alcohols, a viscosity enhancer, and water; the pH range of the liquid preparation is 2.5 to 7.5, and the content of ketamine in the liquid preparation is 0.7% w / v to 8.4% w / v.

[0012] The third aspect of the present application specifically provides a ketamine liquid preparation, which includes ketamine or a pharmaceutically acceptable salt thereof, at least two lower alcohols, a viscosity enhancer, a flavoring agent and water; the pH range of the liquid preparation is 2.5 to 7.5; the content of ketamine hydrochloride in the liquid preparation is 0.7% w / v to 8.4% w / v.

[0013] The fourth aspect of the present application provides the use of the above-mentioned ketamine liquid preparation in the preparation of a drug for preventing, alleviating or treating depression, wherein the drug can be used to treat major depression, unipolar depression, refractory depression, intractable depression, anxious depression, and bipolar depression.

[0014] In a fifth aspect, the present application provides a method for preventing, alleviating or treating depression in a patient using the above-mentioned ketamine liquid preparation, the method comprising administering a therapeutically effective amount of the ketamine liquid preparation to the patient.

[0015] The sixth aspect of the present application provides the above-mentioned ketamine liquid preparation for use in preventing, alleviating or treating depression in patients, wherein the depression is major depression, unipolar depression, refractory depression, intractable depression, anxious depression, or bipolar depression.

[0016] In a seventh aspect, the present application provides a method for preparing the aforementioned ketamine liquid preparation.

[0017] Summary of the Figures

[0018] The accompanying drawings are used to provide an understanding of the technical solution of the present application and constitute a part of the specification. Together with the embodiments of the present application, they are used to explain the technical solution of the present application and do not constitute a limitation on the technical solution of the present application.

[0019] FIG1 is a diagram of an in vitro diffusion experiment of the ketamine liquid preparation of the present application;

[0020] FIG2 is a plasma pharmacokinetic diagram of esketamine preparations of different administration routes proposed in this application;

[0021] FIG3 is a cerebrospinal fluid pharmacokinetic diagram of esketamine preparations for different administration routes proposed in this application.

[0022] Details

[0023] In a first aspect, the present application provides a ketamine liquid preparation for oral mucosal administration, comprising ketamine or a pharmaceutically acceptable salt thereof at a concentration of 0.5% w / v to 8.5% w / v, at least two lower alcohols, and water.

[0024] In one embodiment, the ketamine can be the (S)-enantiomer of ketamine or the (R)-enantiomer of ketamine. In another embodiment, the (S)-enantiomer of ketamine is also known as S-ketamine, esketamine, (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride, etc.; in another embodiment, the (R)-enantiomer of ketamine is also known as R-ketamine, (R)-ketamine, akeketamine, levoketamine, arketamine, d-ketamine, (2R)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone, etc.; in another embodiment, the ketamine is a mixture of the (R)-enantiomer of ketamine and the (S)-enantiomer of ketamine, for example, a mixture of the (R)-enantiomer of ketamine and the (S)-enantiomer of ketamine in equal molar ratios.

[0025] In one embodiment, the liquid preparation of the present application contains at least two lower alcohols, and the lower alcohols are selected from: C1-C6 fatty alcohols, such as ethanol, n-propanol, isopropanol, n-butanol, isobutanol, ethylene glycol, propylene glycol, glycerol, sorbitol, mannitol, butylene glycol, hexylene glycol, etc.

[0026] In the embodiments of the present application, the C1-C6 fatty alcohol specifically refers to an alcohol formed by connecting a hydroxyl group and a saturated fatty hydrocarbon group containing 1 to 6 carbon atoms.

[0027] In one embodiment, the liquid preparation of the present application comprises two lower alcohols, and the two lower alcohols are ethanol and glycerol (or glycerin).

[0028] In one embodiment, the liquid formulation of the present application comprises ethanol and glycerol, wherein the weight ratio of ethanol to glycerol is (0.5 to 100):1, preferably 3.95:1.32.

[0029] In one embodiment, the liquid preparation of the present application comprises two lower alcohols, and the two lower alcohols are sorbitol and glycerol (or glycerin).

[0030] In one embodiment, the liquid preparation of the present application comprises sorbitol and glycerol, wherein the weight ratio of sorbitol to glycerol is (0.5 to 100):1, preferably 4.8:1.32.

[0031] The ketamine liquid formulation described herein has high bioavailability. Therefore, it can be prepared at a relatively low concentration, meeting the preventive or therapeutic needs of clinical patients while avoiding the risk of abuse associated with high-concentration administration. Furthermore, the ketamine liquid formulation exhibits good compatibility with saliva, reducing mucosal irritation and lowering drug side effects. Furthermore, the ketamine liquid formulation exhibits excellent stability even in the absence of preservatives and / or antioxidants.

[0032] In one embodiment, the concentration of ketamine in the liquid formulation is 0.7% w / v to 8.4% w / v; in another embodiment, the concentration of ketamine in the liquid formulation is 1.4% w / v to 6.8% w / v; in yet another embodiment, the concentration of ketamine in the liquid formulation is 1.4% w / v to 6.4% w / v. In yet another embodiment, the concentration of ketamine in the liquid formulation is 0.7% w / v, 0.8% w / v, 0.9% w / v, 1.0% w / v, 1.1% w / v, 1.2% w / v, 1.3% w / v, 1.4% w / v, 1.5% w / v, 1.6% w / v, 1.7% w / v, 1.8% w / v, 1.9% w / v, 2.0% w / v, 2.1% w / v, 2.2% w / v, 2.3% w / v, 2.4% w / v, 2.6% w / v, 2.7% w / v, 2.8% w / v, 2.9% w / v, 3.0% w / v, 3.1% w / v, 3.2% w / v, 3.3% w / v, 3.4% w / v, 3.5% w / v, 3.6% w / v, 3.7% w / v, 3.8% w / v, 3.9% w / v, 4.1% w / v, 4.2% w / v, 4.3% w / v, 4.4% w / v 4% w / v, 2.5% w / v, 2.6% w / v, 2.7% w / v, 2.8% w / v, 2.9% w / v, 3.0% w / v, 3.1% w / v, 3.2% w / v, 3.3% w / v, 3.4 %w / v, 3.5%w / v, 3.6%w / v, 3.7%w / v, 3.8%w / v, 3.9%w / v, 4.0%w / v, 4.1%w / v, 4.2%w / v, 4.3%w / v, 4.4% w / v, 4.5% w / v, 4.6% w / v, 4.7% w / v, 4.8% w / v, 4.9% w / v, 5.0% w / v, 5.1% w / v, 5.2% w / v, 5.3% w / v, 5.4%w / v, 5.5% w / v, 5.6% w / v, 5.7% w / v, 5.8% w / v, 5.9% w / v, 6.0% w / v, 6.1% w / v, 6.2% w / v, 6.3% w / v, 6.4% w / v, 6.5% w / v, 6.6% w / v, 6.7% w / v, 6.8% w / v, 6.9% w / v, 7.0% w / v, 7.1% w / v, 7.2% w / v, 7.3% w / v, 7.4% w / v , 7.5% w / v, 7.6% w / v, 7.7% w / v, 7.8% w / v, 7.9% w / v, 8.0% w / v, 8.1% w / v, 8.2% w / v, 8.3% w / v or 8.4% w / v.

[0033] In one embodiment, acids that can form pharmaceutically acceptable salts with ketamine include hydrochloric acid, sulfuric acid, phosphoric acid, maleic acid, acetic acid, adipic acid, alginic acid, citric acid, aspartic acid, benzoic acid, benzenesulfonic acid, hydrogen sulfate, butyric acid, camphoric acid, camphorsulfonic acid, digluconic acid, fumaric acid, glycerophosphate, stearyl heptanoic acid, hexanoic acid, hydrobromic acid, lactic acid, methanesulfonic acid, nicotinic acid, oxalic acid, pamoic acid, pectic acid, persulfuric acid, 3-phenylpropionic acid, picric acid, pivalic acid, propionic acid, succinic acid, tartaric acid, thiocyanic acid, glutamic acid, p-toluenesulfonic acid, undecanoic acid, and mandelic acid.

[0034] In one embodiment, pharmaceutically acceptable salts that can be formed with ketamine include hydrochloride, sulfate, phosphate, maleate, acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, fumarate, glycerophosphate, stearyl heptanoate, hexanoate, hydrochloride, hydrobromide, hydrogen iodide, lactate, methanesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, glutamate, bicarbonate, p-toluenesulfonate, undecanoate, and mandelate.

[0035] In one embodiment, the concentration of the total of the lower alcohols (i.e., the total of the two lower alkanols) in the liquid preparation is 5.5% w / v to 30% w / v. In another embodiment, the concentration of one lower alcohol in the liquid preparation is 6.0% w / v to 26.3% w / v. In yet another embodiment, the concentration of one lower alcohol in the liquid preparation is 6.1% w / v, 6.2% w / v, 6.3% w / v, 6.4% w / v, 6.5% w / v, 6.6% w / v, 6.7% w / v, 6.8% w / v, 6.9% w / v, 7.0% w / v, 8.0% w / v, 9.0% w / v, 10.0% w / v, 11.0% w / v, 12.0% w / v, 13.0% w / v, 14.0% w / v, 15.0% w / v, 16.0% w / v, 17.0% w / v, 18.0% w / v, 19.0% w / v, 20.0% w / v, 21.0% w / v, 22.0% w / v, 23.0% w / v, 24.0% w / v, 25.0% w / v, 26.0% w / v, 27.0% w / v, 28.0% w / v, 29.0% w / v, 30.0% w / v, 31.0% w / v, 32.0% w / v, 33.0% w / v, 34.0% w / v, 35.0% w / v, 36.0% w / v, 37.0% w / v, 38.0% w / v, 39.0% w / v, v, 13.0% w / v, 14.0% w / v, 15.0% w / v, 16.0% w / v, 17.0% w / v, 18.0% w / v, 19.0% w / v, 19.7% w / v , 20.0% w / v, 21.0% w / v, 22.0% w / v, 23.0% w / v, 24.0% w / v, 25.0% w / v, 26.0% w / v or 26.3% w / v.

[0036] In one embodiment, the pH of the liquid formulation is 2.5 to 7.5.

[0037] In one embodiment, the pH range of the liquid formulation is 4.0 to 7.0; in another embodiment, the pH range of the liquid formulation is 5.0 to 7.0; in yet another embodiment, the pH of the liquid formulation is 5.5 to 7.0; in yet another embodiment, the pH of the liquid formulation is 7.0 to 7.5; in yet another embodiment, the pH of the liquid formulation is 4.5 to 5.5; in yet another embodiment, the pH of the liquid formulation is 2.5, 2.6, 2.7, 2.8, 2.9, 3.0 , 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4 or 7.5.

[0038] In one embodiment, the liquid ketamine formulation further comprises a viscosity increasing agent.

[0039] In one embodiment, the viscosity increasing agent is one of liquid maltitol, xanthan gum, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, methylcellulose, ethyl cellulose, hydroxyethyl cellulose, polyvinyl alcohol, caprylic and capric mono- and diglycerides, carbomer, or polyvinyl pyrrolidone, or a combination thereof.

[0040] In one embodiment, the ketamine liquid preparation further comprises one or more of the following excipients: a flavoring agent, an osmotic pressure regulator, and a preservative.

[0041] In one embodiment, the present application provides a ketamine liquid formulation that also includes a flavoring agent. Flavoring agents can mask any unpleasant odors of the pharmaceutical composition, improving its palatability and promoting patient compliance. In one embodiment, the flavoring agent of the liquid formulation is sodium saccharin, fructose, sucralose, stevioside (or steviol glycoside), menthol, maltitol, xylitol, aspartame, cyclamate, saccharin, neohesperidin, thaumatin, stevia, or acesulfame potassium, or a combination thereof.

[0042] In one embodiment, the present application provides a ketamine liquid preparation, wherein the concentration of the flavoring agent is 0.5-2.5% w / v; in another embodiment, the concentration of the flavoring agent is 1.0-2.0% w / v; in yet another embodiment, the concentration of the flavoring agent is 1.0% w / v, 1.1% w / v, 1.2% w / v, 1.3% w / v, 1.4% w / v, 1.5% w / v, 1.6% w / v, 1.7% w / v, 1.8% w / v, 1.9% w / v or 2.0% w / v.

[0043] In one embodiment, the present application provides a ketamine liquid formulation, which further comprises a buffer. The buffer can be citric acid, sodium dihydrogen phosphate, disodium hydrogen phosphate, acetic acid, boric acid, sodium borate, succinic acid, tartaric acid, lactic acid, fumaric acid, malic acid, trisodium phosphate (trisodium phosphate dodecahydrate or TSP), sodium benzoate, benzoic acid, sodium hydroxide, potassium hydroxide, alkali metal carbonate, sodium carbonate, imidazole, pyrophosphate, sodium gluconate, sodium lactate, phosphoric acid, borate, bicarbonate, Tris-HCl, citrate, or a combination thereof.

[0044] The buffer described in the present application can maintain the pH of the liquid preparation within a stable range, which is beneficial to improving the stability of the solution preparation. The concentration of the buffer is 0.1-0.3% w / v; in one embodiment, the concentration of the buffer is 0.1-0.2% w / v; in another embodiment, the concentration of the buffer is 0.1-0.15% w / v; in another embodiment, the concentration of the buffer is 0.1% w / v, 0.11% w / v, 0.12% w / v, 0.13% w / v, 0.14% w / v, 0.16% w / v, 0.17% w / v, 0.18% w / v, 0.19% w / v, 0.20% w / v, 0.21% w / v, 0.22% w / v, 0.23% w / v, 0.24% w / v, 0.26% w / v, 0.27% w / v, 0.28% w / v, 0.29% w / v, 0.30% w / v, 0.31% w / v, 0.32% w / v, 0.33% w / v, 0.34% w / v, 0.36% w / v, 0.37% w / v, 0.38% w / v, 0.39% w / v, 0.40% w / v, 0.41% w / v, 0.42% w / v, 0.43% w / v, 0.44% w / v, 0.45% w / v, 0.46% w / v, 0.47% w / v, 0.48% w / v, 0.49% w / v, 0.50% w / v, 0.51% w / v, 0.52% w / v, 0.5 .15% w / v, 0.16% w / v, 0.17% w / v, 0.18% w / v, 0.19% w / v, 0.2% w / v, 0.21% w / v, 0.22% w / v, 0.23% w / v, 0.24% w / v, 0.25% w / v, 0.26% w / v, 0.27% w / v, 0.28% w / v, 0.29% w / v, 0.3% w / v.

[0045] In one embodiment, the present application provides a ketamine liquid formulation, which further comprises an antioxidant. The antioxidant of the liquid formulation is ethylenediaminetetraacetic acid (EDTA, edetic acid) or its sodium salt (e.g., disodium edetate) or calcium salt, vitamin E, gallate, sodium bisulfite, ascorbic acid or its salt, butylated hydroxyanisole, or tocopherol, or a combination thereof.

[0046] In one embodiment, the present application provides a ketamine liquid preparation, wherein the concentration of the antioxidant is 0.010-0.020% w / v; in another embodiment, the concentration of the antioxidant is 0.010-0.015% w / v.

[0047] In one embodiment, the ketamine liquid formulation further comprises a preservative. In one embodiment, the preservative is selected from one or more of methylparaben, ethylparaben, propylparaben, butylparaben, sodium methylparaben, sodium ethylparaben, sodium propylparaben, sodium butylparaben, sorbic acid, potassium sorbate, sodium sorbate, benzoic acid, sodium benzoate, benzyl alcohol, benzalkonium bromide, benzalkonium chloride, chlorobutanol, resorcinol, and sodium edetate.

[0048] In one embodiment, the ketamine liquid formulation further comprises an osmotic pressure regulator. In one embodiment, the osmotic pressure regulator is selected from one or more of sodium chloride, potassium nitrate, boric acid, and glucose; preferably, sodium chloride.

[0049] In one embodiment, the liquid ketamine formulation does not contain a preservative, an antioxidant, or a preservative and an antioxidant.

[0050] In a second aspect, the present application provides a ketamine liquid preparation comprising ketamine or a pharmaceutically acceptable salt thereof, at least two lower alcohols, a viscosity enhancer, and water; the pH range of the liquid preparation is 2.5 to 7.5, and the content of ketamine in the liquid preparation is 0.7% w / v to 8.4% w / v.

[0051] In one embodiment, the types of the viscosity enhancers and their contents with the lower alcohol are as described above.

[0052] In a third aspect, the present application provides a ketamine liquid preparation comprising ketamine or a pharmaceutically acceptable salt thereof, at least two lower alcohols, a viscosity enhancer, a flavoring agent, and water; the pH range of the liquid preparation is 2.5 to 7.5; and the content of ketamine hydrochloride in the liquid preparation is 0.7% w / v to 8.4% w / v.

[0053] In one embodiment, the types of the viscosity enhancer and flavoring agent and their contents with the lower alcohol are as described above.

[0054] In one embodiment, the present application provides a ketamine liquid preparation, wherein the flavoring agent is saccharin sodium.

[0055] In a fourth aspect, the present application provides the use of the above-mentioned ketamine liquid preparation in the preparation of a drug for preventing, alleviating or treating depression, wherein the drug can be used to treat major depression, unipolar depression, refractory depression, intractable depression, anxious depression, and bipolar depression.

[0056] In one embodiment, the present application provides a use of the above-mentioned ketamine liquid preparation in the preparation of a drug for preventing, alleviating or treating depression, wherein the liquid preparation is applied to the buccal membrane of the patient's mouth.

[0057] In a fifth aspect, the present application provides a method for preventing, alleviating or treating depression in a patient using the above-mentioned ketamine liquid preparation, comprising administering a therapeutically effective amount of the above-mentioned ketamine liquid preparation to the patient.

[0058] In one embodiment, the present application provides a method for preventing, alleviating or treating depression in patients using the above-mentioned ketamine liquid preparation, wherein the depression is major depression, unipolar depression, refractory depression, intractable depression, anxious depression, or bipolar depression.

[0059] In one embodiment, the present application provides a method for preventing, alleviating or treating depression in a patient using the above-mentioned ketamine liquid formulation, wherein the liquid formulation is applied to the buccal membrane of the patient's mouth.

[0060] In a sixth aspect, the present application provides the above-mentioned ketamine liquid preparation for use in preventing, alleviating or treating depression in patients, wherein the depression is major depression, unipolar depression, refractory depression, intractable depression, anxious depression, or bipolar depression.

[0061] In one embodiment, the ketamine liquid formulation provided herein is used to prevent, alleviate or treat depression in a patient, and the liquid formulation is administered to the buccal membrane of a mammal.

[0062] In a seventh aspect, the present application provides a method for preparing the aforementioned ketamine liquid preparation, comprising the following preparation steps:

[0063] a) weighing a prescribed amount of ketamine or a pharmaceutically acceptable salt thereof, adding purified water, stirring thoroughly to dissolve, and then sequentially adding a prescribed amount of an optional flavoring agent such as saccharin sodium, stirring thoroughly to dissolve;

[0064] b) adding the two lower alcohols and an optional viscosity-increasing agent in the prescription, stirring and dissolving them thoroughly;

[0065] c) adjusting the pH to the corresponding value with sodium hydroxide;

[0066] d) Transfer the solution to a specific volumetric flask and add water to the mark;

[0067] e) After the volume is fixed, the solution is filtered through a 0.45 μm filter membrane, and the filtrate is filled into a pre-filled syringe to obtain the finished preparation.

[0068] The beneficial effects of this application are as follows:

[0069] (1) The ketamine liquid preparation provided in this application can promote the penetration of the active substance into the oral mucosa by using a composition formed by two lower alcohols; and by further adding a viscosity enhancer, the retention time of the liquid preparation in the oral mucosa is increased.

[0070] (2) The ketamine liquid preparation provided in this application is simple and easy to administer, which greatly increases patient compliance. Due to the small dosage and volume, it can greatly reduce irritation to the mucous membrane and reduce the risk of abuse.

[0071] Unless otherwise indicated, all ingredient concentrations are expressed in weight / volume % (% w / v). As is commonly understood, % w / v values ​​refer to the amount of a particular component or ingredient in a formulation. It is well known that equivalent concentrations can be expressed in different units. For example, a concentration of 0.1% w / v can also be expressed as 1 mg / ml of solution.

[0072] Other features and advantages of the present application will be described in the following description, and in part will become apparent from the description, or will be understood by practicing the present application. Other advantages of the present application can be realized and obtained by the solutions described in the description and the drawings.

[0073] The present application discloses a liquid formulation of ketamine for oral mucosal administration and its use. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in this application. The methods and applications of this application have been described through preferred embodiments. Relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of this application to implement and apply the technology of this application. The reagents or instruments used in this application can all be purchased from the market.

[0074] Example 1

[0075] prescription:

[0076] The preparation method comprises the following steps:

[0077] a) Weighing the prescribed amount of esketamine hydrochloride, adding it to 80% of the total mass of purified water, adding an appropriate amount of liquid maltitol and stirring thoroughly to dissolve, and then adding the prescribed amount of fructose and stirring thoroughly to dissolve;

[0078] b) Add the prescribed amount of anhydrous ethanol and glycerol and stir thoroughly to dissolve;

[0079] c) adjusting the pH to 4.5-5.5 with sodium hydroxide;

[0080] d) Transfer the solution to a specific volumetric flask and add liquid maltitol to the mark of 20 ml;

[0081] e) After the volume is fixed, the solution is filtered through a 0.45 μm filter membrane, and the filtrate is filled into 1 ml pre-filled syringes (purchased from Shandong Zibo Minkang Pharmaceutical Packaging Co., Ltd.), 1 ml per syringe to obtain the finished preparation.

[0082] Example 2

[0083] prescription:

[0084] The preparation method is the same as that of Example 1, and the pH is adjusted to 7.0-7.5.

[0085] Example 3

[0086] prescription:

[0087] The preparation method is the same as that of Example 1, and the pH is adjusted to 4.5-5.5.

[0088] Example 4 Stability Test of Ketamine Liquid Formulation of the Present Application

[0089] Ketamine liquid preparations are prone to produce the following two impurities during preparation and storage:

[0090] The above two impurities can be purchased through commercial channels.

[0091] The present inventors conducted a long-term stability experiment on the samples prepared in Examples 1 and 2 in an environment of 25°C±2°C and RH60%±5%.

[0092] 1. Ketamine content detection method:

[0093] Determined by high performance liquid chromatography (General Rule 0512)

[0094] Chromatographic conditions: octadecylsilane bonded silica gel was used as the filler; 0.95 g of sodium hexanesulfonate was dissolved in 1 L of a mixture of acetonitrile and water (acetonitrile:water = 25:75), and then 4 ml of glacial acetic acid was added and mixed to form the mobile phase; the detection wavelength was 215 nm; the flow rate was 1.0 ml per minute; the column temperature was 30°C; and the injection volume was 20 μl.

[0095] 2. Methods for detecting ketamine-related substances:

[0096] Determined according to high performance liquid chromatography (General Rule 0512).

[0097] Chromatographic conditions: Octadecylsilane bonded silica gel as the packing (Agela MP C18 4.6×150 mm, 5 μm or equivalent); 25 mM phosphate buffer (dissolve 3.4 g of potassium dihydrogen phosphate in 1000 ml of water and adjust the pH to 2.5 with phosphoric acid) as mobile phase A, and acetonitrile as mobile phase B. Gradient elution was performed according to the table below, with detection at a wavelength of 215 nm; column temperature was 30°C; flow rate was 1.0 ml / min; injection volume was 20 μl.

[0098] Table 3: Long-term test results of Examples 1-2

[0099] The results of the long-term test shown in Table 3 show that the total impurities of the ketamine liquid preparation do not exceed 0.5% and the maximum single impurity does not exceed 0.3% when the pharmaceutical preparation obtained in the present application is placed at room temperature for up to 3 months. The quality of the ketamine liquid preparation still meets the quality standards and is stable.

[0100] Example 5 In vitro diffusion test of the ketamine liquid preparation of the present application

[0101] This study used the Franz diffusion cell method and selected phospholipid biomimetic barrier (Bionic membrane) simulates oral mucosa, and PBS buffer is used as the diffusion medium; after the diffusion cell reaches 37°C, 0.5 ml of artificial saliva is added to the top of the bionic membrane, and then 0.2 ml of the solution prepared in Example 1 and Example 2 are added. In vitro permeation tests are performed respectively, and the sampling time points are 10 min, 20 min, 30 min, 45 min, 60 min, 90 min, 120 min, and 180 min. 1 ml of sample is taken at each time point, and the content is detected by liquid phase.

[0102] Table 4: In vitro permeation results of Examples 1-2

[0103] Comparative Example 1 Esketamine Hydrochloride Nasal Spray (prepared according to patent CN 111297803 A)

[0104] Prescription ingredients

[0105] Product specifications: Each spray contains 14.00 mg of esketamine

[0106] The preparation method comprises the following steps:

[0107] a) Weighing the prescribed amount of dexketamine hydrochloride, adding a certain amount of purified water, stirring thoroughly to dissolve, and then sequentially adding the prescribed amount of edetate disodium and citric acid, stirring thoroughly to dissolve;

[0108] b) adjusting the pH to 4.5 with sodium hydroxide;

[0109] c) Transfer the solution to a specific volumetric flask and add water to the mark;

[0110] d) After the volume is fixed, the solution is filtered through a 0.45 μm filter membrane and the filtrate is filled as required.

[0111] Test Example 1 In vivo pharmacokinetic experiment

[0112] 1. Experimental Grouping

[0113] Table 5: Animal grouping

[0114] 2. Experimental plan

[0115] This experiment used Beagle dogs weighing 7.80 kg to 9.42 kg, with three dogs per group. Upon arrival, qualified personnel performed a health examination and provided at least 14 days of adaptive husbandry and acclimatization. Only qualified animals meeting the experimental requirements were selected for the trial.

[0116] Dosage:

[0117] Group 1: Secure the animal, tilt the head upward so the nasal cavity is horizontal, and insert approximately 1 cm into the nasal cavity. Deliver one spray (0.1 mL / spray) into each nostril, ensuring that each animal receives the drug through the same nostril. Hold the dog's head horizontally for 2 minutes and observe for drug discharge. Return the animal to its cage after confirming no drug discharge. Dosage should be slow to avoid choking or drug leakage, which could reduce the amount delivered and affect the test results.

[0118] Groups 2-4: Dogs were anesthetized with an intramuscular injection of Zoltrate 50 (dose 8-10 mg / kg, concentration 50 mg / mL). While anesthetized, the dogs' tongues were fixed and the dogs were placed on their side on the operating table. A syringe containing the test product was placed in the buccal administration site with the cap removed. The plunger was pushed to allow the drug to flow out for 5 minutes. Dosing was performed using either the left or right buccal membrane. The dogs were expected to salivate for 15 minutes after dosing and were unable to swallow. The saliva was allowed to flow naturally without manipulation. The area of ​​the towel moistened with saliva was recorded. The procedure was consistent for all dogs receiving buccal dosing.

[0119] Comparative Example 1 used unilateral nasal administration, with a dosage of 0.1 ml / mouse (1 spray) and a dosage of 14 mg; Experimental Example 3 used unilateral buccal liquid administration, with a dosage of 0.25 ml / mouse and a dosage of 14 mg.

[0120] At each time point, about 0.3 mL of whole blood was collected from the subcutaneous vein of the forelimb or hindlimb of each group of animals. The time points for blood collection were: 0 min (before administration), 2 min, 5 min, 10 min, 15 min, 30 min, 60 min, 2 h, 4 h, 6 h, and 8 h.

[0121] Plasma sample processing: Before blood collection, place the centrifuge tube containing EDTA-K2 in an ice box filled with crushed ice. Collected blood was added to the centrifuge tube, inverted manually at least five times, and stored in an ice box filled with crushed ice. Centrifuge at 2000 g for 10 minutes at 2-8°C, completing the centrifugation within 1 hour of blood collection. After centrifugation, transfer the plasma to a newly labeled tube, store temporarily and transport in an ice box filled with crushed ice, and store below -60°C. Samples were managed using Watson LIMS 7.5.

[0122] Cerebrospinal fluid (CSF) sample collection: Approximately 0.2 mL of CSF was collected from the lumbar vertebrae or foramen magnum of each animal in each group at each time point. CSF was collected at 0 min (before dosing), 15 min, 1 h, and 4 h. After collection, samples were temporarily stored and transported in an ice box filled with crushed ice and stored below -60°C. Samples were managed using Watson LIMS 7.5.

[0123] 3. Experimental results

[0124] Table 6: Concentration-time changes of esketamine in Beagle dog plasma after administration of two formulations by different routes

[0125] Table 7: Concentration-time changes of esketamine in the cerebrospinal fluid of Beagle dogs after administration of two formulations by different routes

[0126] Table 8: Pharmacokinetic results of esketamine in Beagle dog plasma after different administration routes of the two formulations

[0127] Table 9: Pharmacokinetic results of esketamine in the cerebrospinal fluid of Beagle dogs after administration of two formulations using different routes

[0128] As shown in Table 8 and Figure 2, for plasma samples, among the different administration routes of esketamine hydrochloride, the buccal administration group (Example 3) had a T max The average C max The data show that compared with the nasal administration group (Comparative Example 1), the buccal administration group (Example 3) has a C maxThe AUC of the buccal administration group (Example 3) of the buccal solution was significantly increased, indicating that the drug absorption of the buccal solution of esketamine hydrochloride in the present application is higher than that of the nasal administration group (Comparative Example 1). last This result is consistent with C max The results are consistent with those of the present invention, which further illustrates that the in vivo drug absorption of esketamine hydrochloride buccal solution administered through buccal membrane is higher than that of nasal administration.

[0129] As shown in Table 9 and Figure 3, for cerebrospinal fluid samples, among the different administration routes of esketamine hydrochloride, the buccal administration group (Example 3) had a T max The average C max The data show that in the cerebrospinal fluid samples, compared with the nasal administration group (Comparative Example 1), the buccal administration group (Example 3) has a C max The AUC of the buccal administration group (Example 3) of the buccal solution was significantly increased, indicating that the drug absorption of the buccal solution of esketamine hydrochloride in the present application is higher than that of the nasal administration group (Comparative Example 1). last The increase was also significant, and this result was consistent with that of C max The results are consistent with those of the present invention, which further illustrates that the in vivo drug absorption of esketamine hydrochloride buccal solution administered through buccal membrane is higher than that of nasal administration.

[0130] In summary, the onset time of the two esketamine hydrochloride preparations by different administration routes is similar, about 0.25h, but the in vivo drug absorption of esketamine hydrochloride via buccal solution and buccal membrane is significantly higher than that via nasal administration.

[0131] The technical solution of the present application can also be used for the buccal liquid and buccal membrane delivery system of R-ketamine, ketamine or pharmaceutically acceptable salts, and the purpose of the present invention can be achieved by adjusting or changing the content of the active ingredient, the type and dosage of pharmaceutical excipients, etc.

[0132] Although the embodiments disclosed in this application are as described above, the contents described are merely embodiments adopted to facilitate understanding of this application and are not intended to limit this application. Any person skilled in the art to which this application belongs may make any modifications and changes in the form and details of the implementation without departing from the spirit and scope disclosed in this application, but the scope of protection of this application shall still be based on the scope defined by the attached claims.

Claims

1. A ketamine liquid preparation for oral mucosal administration, comprising ketamine or a pharmaceutically acceptable salt thereof at a concentration of 0.5% w / v to 8.5% w / v, at least two lower alcohols, and water.

2. The ketamine liquid preparation according to claim 1, wherein The ketamine may be one of its two enantiomers, esketamine or R-ketamine, or a mixture of the two.

3. The ketamine liquid preparation according to claim 1, wherein The concentration of ketamine in the liquid preparation is 0.7% w / v to 8.4% w / v; preferably, 1.4% w / v to 6.8% w / v; more preferably, 1.4% w / v to 6.4% w / v.

4. The ketamine liquid preparation according to claim 1, wherein The lower alcohol is selected from ethanol, propanol, isopropanol, butanol, isobutanol, ethylene glycol, propylene glycol, glycerol, sorbitol, mannitol, butylene glycol, and hexylene glycol.

5. The ketamine liquid preparation according to claim 4, wherein The two lower alcohols are ethanol and glycerol, or sorbitol and glycerol.

6. The ketamine liquid preparation according to claim 5, wherein: The weight ratio of ethanol to glycerol is (0.5 to 100):1, preferably 3.95:1.32; or the weight ratio of sorbitol to glycerol is (0.5 to 100):1, preferably 4.8:1.

32.

7. The ketamine liquid preparation according to any one of claims 1 to 6, wherein The total concentration of the lower alcohols is 5.5% w / v to 30% w / v, preferably, 6.0% w / v to 26.3% w / v.

8. The ketamine liquid preparation according to any one of claims 1 to 7, wherein The pH range of the liquid preparation is 2.5 to 7.5; preferably, 4.0 to 7.0; more preferably, 5.0 to 7.

0.

9. The ketamine liquid preparation according to any one of claims 1 to 8, further comprising a viscosity enhancer.

10. The ketamine liquid preparation according to claim 9, wherein The viscosity enhancer is one of liquid maltitol, xanthan gum, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, methylcellulose, ethyl cellulose, hydroxyethyl cellulose, polyvinyl alcohol, caprylic acid capric acid mono- and diglycerides, carbomer and polyvinyl pyrrolidone, or a combination thereof.

11. The ketamine liquid preparation according to any one of claims 1 to 8, further comprising one or more of the following excipients: a buffer, a flavoring agent, an antioxidant, an osmotic pressure regulator, and a preservative.

12. The ketamine liquid preparation according to claim 11, wherein The flavoring agent is one of saccharin sodium, fructose, sucralose, stevioside, menthol, maltitol, xylitol, aspartame, sodium cyclamate, saccharin, neohesperidin, thaumatin, stevia and acesulfame potassium, or a combination thereof; and / or The buffer can be citric acid, sodium dihydrogen phosphate, disodium hydrogen phosphate, acetic acid, boric acid, sodium borate, succinic acid, tartaric acid, lactic acid, fumaric acid, malic acid, trisodium phosphate (trisodium phosphate dodecahydrate or TSP), sodium benzoate, benzoic acid, sodium hydroxide, potassium hydroxide, alkali metal carbonate, sodium carbonate, imidazole, pyrophosphate, sodium gluconate, sodium lactate, phosphoric acid, borate, bicarbonate, Tris-HCl, citrate, or a combination thereof; and / or The antioxidant is ethylenediaminetetraacetic acid or its sodium salt or calcium salt, vitamin E, gallate, sodium bisulfite, ascorbic acid or its salt, butylated hydroxyanisole or tocopherol, or a combination thereof; and / or The osmotic pressure regulator is selected from one or more of sodium chloride, potassium nitrate, boric acid and glucose; and / or The preservative is selected from methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, methyl parahydroxybenzoate sodium, ethyl parahydroxybenzoate sodium, propyl parahydroxybenzoate sodium, butyl parahydroxybenzoate sodium, sorbic acid, potassium sorbate, sodium sorbate, benzoic acid, sodium benzoate, benzyl alcohol, benzalkonium bromide, One or more of benzalkonium chloride, chlorobutanol, resorcinol and sodium edetate.

13. The ketamine liquid preparation according to any one of claims 1 to 8, wherein The liquid preparation does not contain preservatives, antioxidants, or preservatives and antioxidants.

14. Use of the ketamine liquid preparation according to any one of claims 1 to 13 in the preparation of a drug for preventing, alleviating or treating depression.

15. The use according to claim 14, wherein The depression is major depression, unipolar depression, refractory depression, intractable depression, anxious depression, or bipolar depression.

16. The use according to claim 14 or 15, wherein The liquid formulation is applied to the buccal membranes of the patient's oral cavity.

17. A method for preventing, alleviating or treating a patient with depression, comprising administering a therapeutically effective amount of the ketamine liquid preparation according to any one of claims 1 to 13 to the buccal membrane of the patient.

18. The method according to claim 17, wherein: The depression is major depression, unipolar depression, refractory depression, intractable depression, anxious depression or bipolar depression.

19. The ketamine liquid preparation according to any one of claims 1 to 13 is used for preventing, alleviating or treating depression in patients.

20. The ketamine liquid preparation according to claim 19 is used for preventing, alleviating or treating depression in patients, wherein: The depression is major depression, unipolar depression, refractory depression, intractable depression, anxious depression or bipolar depression.

21. The ketamine liquid preparation according to claim 19 or 20 is used for preventing, alleviating or treating depression in patients, wherein: The liquid formulation is applied to the buccal membranes of the patient's oral cavity.

Citation Information

Patent Citations

  • Oral thin film with high active agent loading

    CN111447920A

  • S-ketamine medicine absorbed through oral mucosa

    CN113712895A

  • Escketamine liquid preparation and application thereof

    CN116942647A

  • Ketamine for the treatment of somatoform pain disorder

    GB201518002D0

  • Oral transmucosal adminstration forms of s-ketamine

    US20140079740A1